Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPAC With Cisplatin-doxorubicin + Systemic Chemotherapy in Advanced Ovarian, Fallopian Tube or Peritoneal Cancer
NCT04811703Phase 1Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Jul 2021
- Primary completion
- Jun 2028
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cisplatin and doxorubicin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Hospices Civils de Lyon. Primary endpoint: Dose-limiting toxicities. Started Jul 2021; status: recruiting.
02
Drugs
cisplatindoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04811703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04811703.